BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 12189744)

  • 1. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
    Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
    Debruyne F; Boyle P; Calais da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman C
    Prog Urol; 2004 Jun; 14(3):326-31. PubMed ID: 15373174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
    Debruyne F; Boyle P; Calais Da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman CC
    Eur Urol; 2004 Jun; 45(6):773-9; disucssion 779-80. PubMed ID: 15149751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
    Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
    Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
    Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
    Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study.
    Ryu YW; Lim SW; Kim JH; Ahn SH; Choi JD
    Urol Int; 2015; 94(2):187-93. PubMed ID: 25614155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
    Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
    Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
    Plosker GL; Brogden RN
    Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
    Stepanov VN; Siniakova LA; Sarrazin B; Raynaud JP
    Adv Ther; 1999; 16(5):231-41. PubMed ID: 10915398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
    Argirović A; Argirović D
    Vojnosanit Pregl; 2013 Dec; 70(12):1091-6. PubMed ID: 24450252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
    Boyle P; Robertson C; Lowe F; Roehrborn C
    BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequently used in its treatment].
    Carballido J; Ruiz-Cerdá JL; Unda M; Baena V; Campoy P; Manasanch J; Slof J
    Actas Urol Esp; 2008 Oct; 32(9):916-25. PubMed ID: 19044302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.
    Hizli F; Uygur MC
    Int Urol Nephrol; 2007; 39(3):879-86. PubMed ID: 17203353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; MacDonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia.
    Pytel YA; Vinarov A; Lopatkin N; Sivkov A; Gorilovsky L; Raynaud JP
    Adv Ther; 2002; 19(6):297-306. PubMed ID: 12665050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.